Compare GBIO & HERZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBIO | HERZ |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 30.5M |
| IPO Year | 2020 | N/A |
| Metric | GBIO | HERZ |
|---|---|---|
| Price | $5.66 | $1.91 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.88 | N/A |
| AVG Volume (30 Days) | ★ 93.6K | N/A |
| Earning Date | 03-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | N/A |
| 52 Week High | $9.25 | N/A |
| Indicator | GBIO | HERZ |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 34.29 |
| Support Level | $5.41 | $1.90 |
| Resistance Level | $5.72 | $1.97 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 78.38 | 50.27 |
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.